Results 211 to 220 of about 3,144,476 (264)

Targeting the NAD+/SIRT1 axis: A metabolic strategy to overcome oxaliplatin resistance in colorectal cancer. [PDF]

World J Gastroenterol
Hussain MS, Jakhmola V, Goyal K, Rekha A, Sultana A, Ali H, Gupta G.   +6 more
europepmc   +1 more source

DIRAS1 Drives Oxaliplatin Resistance in Colorectal Cancer via PHB1-Mediated Mitochondrial Homeostasis. [PDF]

Biology (Basel)
Long M, Ouyang Q, Wen J, Zeng X, Xu Z, Zhong S, Huang C, Luo JL.   +7 more
europepmc   +1 more source

Alectinib and SALL4-Targeted Fatty Acid Oxidation: A Strategy to Combat Oxaliplatin Resistance in Gastric Cancer. [PDF]

Turk J Gastroenterol
Xiao Y, Fang K, Liao J, Zhou H, Zhu W, Liu Z, Ouyang H, Liu K.   +7 more
europepmc   +1 more source

DEPP1: A prognostic biomarker linked to stroma‑rich and immunosuppressive microenvironment, promoting oxaliplatin resistance in gastric cancer. [PDF]

Oncol Rep
Qiu X, Pan T, Kuang T, Shen Y, Zheng Y, Geng H, Ni B, Xia X, Zhu C, Zhang Z, Cao H, Tu L.   +11 more
europepmc   +1 more source

Research Progress on Reversing Oxaliplatin Resistance in Colon Cancer

Advances in Clinical Medicine, 2023
openaire   +1 more source

RETRACTION: LncRNA NR2F1-AS1 Regulates Hepatocellular Carcinoma Oxaliplatin Resistance by Targeting ABCC1 via miR-363. [PDF]

J Cell Mol Med
europepmc   +1 more source

Increased keratin 80 expression predicts poor prognosis and promotes oxaliplatin resistance in gastric cancer. [PDF]

World J Gastroenterol
Yang B, Cao HX, He YW, Ouyang JJ, Lv M, Li YX, Lu YD.   +6 more
europepmc   +1 more source

Modeling oxaliplatin resistance in colorectal cancer reveals a SERPINE1-based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype. [PDF]

Cell Death Dis
Wong SQR, Das M, Tenzin K, Shirgaonkar N, Chua H, Chee LX, Sae Yeoh A, Murugiah AA, Chua WY, Theardy MS, Subel EJ, Thangavelu MT, Chan JV, Yap CK, Tan IBH, Tsantoulis P, Tejpar S, Loo JM, DasGupta R.   +18 more
europepmc   +1 more source

Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway. [PDF]

Front Cell Dev Biol
Li H, Wang C, Lan L, Wu W, Evans I, Ruiz EJ, Yan L, Zhou Z, Oliveira JM, Reis RL, Hu Z, Chen W, Behrens A, He Y, Zhang C.   +14 more
europepmc   +1 more source

Correction: THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer. [PDF]

Mol Cancer
Zhou X, Han J, Zuo A, Ba Y, Liu S, Xu H, Zhang Y, Weng S, Zhou Z, Liu L, Luo P, Cheng Q, Zhang C, Chen Y, Shan D, Liu B, Yang S, Han X, Deng J, Liu Z.   +19 more
europepmc   +1 more source